FTC Seeks to Block Sanofi’s Acquisition of Rare Disease Drug that ...
Dec 11, 2023 · Sanofi is a monopoly supplier of Food and Drug Administration (FDA) approved drugs to treat the disease. According to the FTC’s complaint, Maze’s Phase 2-ready developmental drug—a glycogen synthase 1 inhibitor called MZE001—threatens to undermine this monopoly as the first oral medication available for Pompe disease patients.
Latest Maze news - BleepingComputer
The infamous Maze ransomware gang announced today that they have officially closed down their ransomware operation and will no longer be leaking new companies' data on their site.
FTC, in unusual move, leads Sanofi to terminate a drug research deal
Dec 12, 2023 · Sanofi terminated a licensing deal with biotechnology company Maze Therapeutics Monday after the Federal Trade Commission filed a lawsuit alleging that the collaboration was designed to extend the French drugmaker’s monopoly in treating a rare disorder known as Pompe disease.
Maze CEO ‘disappointed’ in Sanofi decision to end partnership
Dec 12, 2023 · W hen Sanofi terminated its partnership with Maze Therapeutics this week to develop an experimental drug for Pompe disease, Maze CEO Jason Coloma did not learn the news in a conference call...
Maze lands new partner for Pompe drug, after Sanofi pact came …
May 10, 2024 · Biotechnology startup Maze Therapeutics has licensed a Pompe disease drug to Shionogi, five months after a challenge from the Federal Trade Commission caused Sanofi to …
Sanofi strikes a $150M deal for Maze’s Pompe disease drug
May 1, 2023 · Maze Therapeutics is licensing its treatment for Pompe disease, a genetic disorder that weakens muscles, to Sanofi for $150 million in cash and equity investment. In a deal announced Monday, Sanofi will acquire rights to develop and commercialize Maze’s drug candidate MZE001, which is slated to begin a Phase 2 study later this year.
Frankie Beverly, lead singer and founder of Maze, dead at 77 - CNN
Sep 11, 2024 · Frankie Beverly, who with his band Maze gave the world an anthem that will forever be tied to cookouts and good times, died on Tuesday, his family announced. He was 77. Beverly’s family...
news, press, & publications - Maze Therapeutics
Nov 13, 2024 · Maze Therapeutics Reports Positive First-in-Human Data from Phase 1 Healthy Volunteer Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease (AKD)
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce …
May 10, 2024 · Maze Therapeutics is a biopharmaceutical company that is harnessing the power of human genetics to transform the lives of patients, with a focus on genetically informed therapies for common diseases such as chronic kidney disease.
Maze News: International News, Local Headlines & Stories | Maze
Read articles on news. Discover headlines classified and ranked in order of popularity. Access the journalist portal to submit your best story.